Hospital
Providence Health System - Southern California
Providence Health System - Southern California was paid $24.26M by Medicaid between Jan 2018 and Dec 2024, across 179 billing codes. Its largest line is 0450, Emergency room services — 39% of everything it billed.
33Billing provider infoPROVIDENCE HEALTH SYSTEM - SOUTHERN CALIFORNIA
SAN PEDRO, CA 90732
SAN PEDRO, CA 90732
33aNPI1942247291assigned 06/02/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$24.26M
24GClaims508,762
24DCodes billed179
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#106 of 410
Median peer was paid$6.90M
This provider vs. median3.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ANDERSON, DONALD controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 81,834 | $2.42M | |
| 2019 | 68,547 | $2.83M | |
| 2020 | 54,167 | $2.11M | |
| 2021 | 66,731 | $2.86M | |
| 2022 | 71,214 | $3.88M | |
| 2023 | 83,952 | $4.93M | |
| 2024incomplete | 82,317 | $5.23M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 39% | 75,212 | 66,071 | $9.58M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.9% | 2,415 | 2,350 | $1.19M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.2% | 3,668 | 3,585 | $1.01M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.7% | 1,750 | 1,717 | $664K |
| 80053 | Comprehensive metabolic panel | 2.7% | 15,019 | 14,070 | $654K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.6% | 16,193 | 14,912 | $639K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 14,966 | 13,965 | $599K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.2% | 12,962 | 11,592 | $530K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 28,367 | 25,516 | $518K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 9,106 | 8,684 | $478K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 12,960 | 12,149 | $464K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.9% | 12,957 | 11,941 | $453K |
167 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 4,538 | $413K |
| 71046 | Radiologic examination, chest; 2 views | 1.6% | 7,847 | $381K |
| 99199 | Unlisted special service, procedure or report | 1.4% | 6,104 | $349K |
| 99285 | Emergency room visit (most serious) | 1.4% | 1,698 | $329K |
| Z7502 | 1.3% | 8,874 | $320K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 7,878 | $309K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 9,095 | $259K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,458 | $242K |
| 81001 | <1% | 23,464 | $242K | |
| 99284 | Emergency room visit (serious) | <1% | 2,907 | $235K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,062 | $233K |
| 83690 | <1% | 12,069 | $201K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,124 | $191K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,344 | $165K |
| 84484 | <1% | 9,194 | $152K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,932 | $136K |
| 99283 | Emergency room visit (moderate) | <1% | 2,649 | $132K |
| 80076 | <1% | 5,536 | $132K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,912 | $126K |
| 87040 | <1% | 3,282 | $123K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,508 | $119K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,191 | $114K |
| 0250 | <1% | 16,574 | $107K | |
| 93975 | <1% | 650 | $88K | |
| 96376 | <1% | 2,424 | $86K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,342 | $85K |
| 83880 | <1% | 4,644 | $78K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 943 | $78K |
| 83605 | <1% | 2,495 | $77K | |
| 76801 | <1% | 1,044 | $77K | |
| J3490 | Unclassified drugs | <1% | 11,944 | $76K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,306 | $73K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 721 | $72K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,976 | $68K |
| 93971 | <1% | 708 | $67K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,417 | $67K |
| 73562 | <1% | 1,505 | $66K | |
| 85610 | <1% | 4,912 | $59K | |
| 73630 | <1% | 1,579 | $59K | |
| 84702 | <1% | 1,368 | $59K | |
| 73610 | <1% | 1,535 | $58K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 96 | $54K |
| 87186 | <1% | 1,395 | $52K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 134 | $45K |
| 73130 | <1% | 1,088 | $42K | |
| 90715 | <1% | 1,263 | $41K | |
| 73030 | <1% | 791 | $36K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,636 | $31K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 134 | $31K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,839 | $29K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,407 | $29K |
| 85730 | <1% | 2,003 | $28K | |
| 87807 | <1% | 1,275 | $28K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,562 | $27K |
| 81003 | <1% | 3,760 | $26K | |
| 87077 | <1% | 1,234 | $25K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,337 | $24K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,336 | $23K |
| 81025 | <1% | 2,358 | $22K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 873 | $22K |
| 80143 | <1% | 922 | $21K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,201 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,518 | $20K |
| 86900 | <1% | 1,957 | $20K | |
| 80179 | <1% | 893 | $20K | |
| 87210 | <1% | 1,009 | $20K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,576 | $19K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 724 | $18K |
| 70498 | <1% | 57 | $18K | |
| 86901 | <1% | 1,971 | $18K | |
| 70496 | <1% | 55 | $17K | |
| 0270 | <1% | 9,117 | $17K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,260 | $16K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 517 | $16K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,335 | $15K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 204 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 745 | $14K |
| 86850 | <1% | 818 | $14K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,135 | $13K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 406 | $11K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 29 | $11K |
| 72100 | <1% | 151 | $10K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 136 | $9K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,309 | $9K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 228 | $8K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,375 | $8K |
| 0762 | <1% | 78 | $8K | |
| 87081 | <1% | 740 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 901 | $8K |
| 0761 | <1% | 264 | $8K | |
| 73110 | <1% | 243 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 365 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,155 | $7K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 567 | $7K |
| 83735 | <1% | 517 | $7K | |
| S9484 | Crisis intervention mental health services, per hour | <1% | 46 | $7K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 74 | $6K |
| 0350 | <1% | 379 | $6K | |
| J1815 | Injection, insulin, per 5 units | <1% | 180 | $4K |
| 84703 | <1% | 181 | $4K | |
| 76770 | <1% | 38 | $3K | |
| 70486 | <1% | 15 | $3K | |
| 73502 | <1% | 56 | $3K | |
| 96367 | <1% | 68 | $2K | |
| 0324 | <1% | 81 | $2K | |
| 85379 | <1% | 268 | $2K | |
| 93017 | <1% | 29 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 29 | $2K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,655 | $2K |
| 82550 | <1% | 113 | $2K | |
| 93970 | <1% | 12 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 155 | $2K |
| Z7610 | <1% | 355 | $2K | |
| 29125 | <1% | 104 | $2K | |
| Z9725 | <1% | 40 | $2K | |
| 85027 | <1% | 163 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 38 | $2K |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 51 | $2K |
| 71101 | <1% | 14 | $2K | |
| 73140 | <1% | 59 | $1K | |
| 0351 | <1% | 229 | $1K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 27 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 119 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 243 | $1K |
| 76870 | <1% | 13 | $1K | |
| 87088 | <1% | 198 | $1K | |
| 73590 | <1% | 27 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $972.05 |
| 97116 | <1% | 65 | $971.80 | |
| 87205 | <1% | 28 | $880.47 | |
| 84100 | <1% | 63 | $850.84 | |
| 0258 | <1% | 44 | $843.36 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 178 | $638.53 |
| 82248 | <1% | 53 | $620.34 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 25 | $608.05 |
| 0710 | <1% | 130 | $566.36 | |
| 73080 | <1% | 15 | $437.34 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 63 | $433.57 |
| 81002 | <1% | 253 | $428.85 | |
| 73090 | <1% | 13 | $399.34 | |
| 0636 | <1% | 1,165 | $345.74 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 29 | $297.70 |
| 82077 | <1% | 16 | $271.17 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25 | $265.70 |
| A4217 | Sterile water/saline, 500 ml | <1% | 28 | $246.63 |
| J2704 | Injection, propofol, 10 mg | <1% | 13 | $234.67 |
| 82010 | <1% | 15 | $220.99 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 30 | $215.10 |
| 87070 | <1% | 12 | $196.89 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 437 | $196.56 |
| 0301 | <1% | 30 | $161.01 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $132.90 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 28 | $130.14 |
| 87420 | <1% | 12 | $128.94 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 149 | $107.20 |
| 86592 | <1% | 13 | $104.26 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 13 | $93.84 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 14 | $87.79 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 32 | $60.07 |
| 0760 | <1% | 22 | $40.54 | |
| 0637 | <1% | 42 | $20.31 | |
| 29130 | <1% | 14 | $6.12 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 14 | $2.51 |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 206 | $0.00 |
| A9270 | Non-covered item or service | 0% | 32 | $0.00 |
| 0305 | 0% | 14 | $0.00 | |
| 0300 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialANDERSON, DONALD (ASSISTANT SECRETARY ENROLLMENTS)
| Provider | Location | Paid |
|---|---|---|
| Providence Health & Services Washington | Anchorage, AK | $161.45M |
| Kadlec Regional Medical Center | Richland, WA | $151.60M |
| Swedish Edmonds | Edmonds, WA | $30.06M |
| ST. Joseph Health Northern California, LLC | Eureka, CA | $28.68M |
| Providence Health System Southern California | Torrance, CA | $27.29M |
| Providence Health & Services - Washington | Tukwila, WA | $21.98M |
| Swedish Health Services | Seattle, WA | $21.06M |
| Providence Health & Services Washington | Kodiak, AK | $11.39M |
| Swedish Health Services | Seattle, WA | $11.08M |
| ST. Joseph Health Northern California, LLC | Fortuna, CA | $8.55M |
| Collabria Care | Napa, CA | $8.20M |
| Providence Health & Services Oregon | Seaside, OR | $8.01M |
| Providence Health & Services- Washington | Spokane, WA | $8.01M |
| Hospice of Lubbock INC | Lubbock, TX | $6.48M |
| Providence Saint John's Health Center | Santa Monica, CA | $5.52M |
| Methodist Hospital Levelland | Levelland, TX | $4.55M |
| Collabria Care | Napa, CA | $4.05M |
| Methodist Hospital Levelland | Levelland, TX | $4.01M |
| Methodist Hospital Plainview Texas | Plainview, TX | $4.00M |
| Providence Medical Institute | Torrance, CA | $3.57M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.